Air Pollution and Cardiovascular Disease in Qatar: an Interventional Study to Reduce Blood Pressure
Recruiting · NCT05903950 · Interventional (participants receive a specific treatment) · Lead sponsor: Weill Cornell Medical College in Qatar
View the official record on ClinicalTrials.gov →Interventions studied
Air cleaners with HEPA filterAir cleaners without HEPA filter
What this trial is about
The main objective is to determine if in-home portable air cleaners provide persistent reductions in PM2.5 exposures and improvements in systolic blood pressure and biochemical parameters over 4-weeks in patients with metabolic syndrome residing in Qatar.
Who can take part
Age range
18 Years to 60 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Non-smokers (100% abstinence from use of any smoking or vaping product during the prior year)
- Age ≥18 and less than 60 years old
- Living in a single residence (home, apartment) located anywhere in Qatar
- Mild systolic hypertension: screening visit systolic BP 130 to 159 mm Hg (off treatment or taking ≤ 2 BP medications that have been stable without changes during prior 4 weeks) plus ≥ 2 more additional criteria for the metabolic syndrome:
- Waist circumference ≥102 cm if male and ≥88 cm if female
- Fasting triglycerides ≥150 mg/dL (or taking a triglyceride-lowering medication)
- HDL-C ≤ 40 mg/dL if male and ≤ 50 mg/dL if female (or taking an HDL-raising medication),
- Fasting glucose ≥100 mg/dL
Exclusion criteria
- Pregnancy (self-reported)
- Screening visit urine positive for cotinine (NicAlert \>100 ng/mL)
- Living with an active smoker who smokes indoors (by self-report)
- High risk conditions that prohibit allowing home BP to be \>130/80 mm Hg during the10-week trial including any cardiovascular disease (coronary artery disease, prior stroke, heart failure, peripheral arterial disease, aneurysm) or ≥ stage 3 kidney disease (estimated glomerular filtration rate \< 60 ml/min)
- A medical condition placing the participant at risk from participation (per investigators)
- Expected overnight travel outside their residence during the study
- HEPA filter within the air conditioners of the residence (self-reported) or individual use of HEPA filter
- Unable to comprehend/sign an informed consent
- Lung disease requiring oxygen
- Cancer receiving treatment
- Screening visit: BP ≥160/100 mm Hg or fasting blood glucose ≥126 mg/dL and confirmed diabetes with follow-up HbA1c ≥6.5%. If glucose is elevated ≥126 mg/dL but HbA1c\<6.5%, they could still participate.
- Medication changes in past 4 weeks. If participants are on medications for high BP or hyperlipidemia, they will need to have had stable therapy during prior 10 weeks with no planned changes during the study
- Left upper arm circumference \>17 inches as this will make BP levels inaccurate with the home monitor used
- Acute illness or infectious symptoms within the prior 4 weeks.
Where it is running
1 location listed.
- Hamad Medical Corporation - Doha, Qatar